Gastroenterology Doctors in Maple Grove, MN Accepting Medicare

6 Gastroenterology doctors found. Showing 1 - 6

Pete Albert Pooler, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9825 Hospital Dr Ste 300, Maple Grove, MN 55369 Phone: 763-587-7900    Fax: 763-494-7501

Dr. Brett Henderson, D.O. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 10150 Niagara Ln N, Maple Grove, MN 55369 Phone: 612-870-5491    Fax: 612-870-5491

Dr. Sarath Vasanth Krishnan, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 10150 Niagara Ln N Ste 210, Maple Grove, MN 55369 Phone: 612-871-1145

Dr. Arunkumar Muthusamy, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 10150 Maple Grove Lane N #210, Maple Grove, MN 55369 Phone: 612-871-1145    Fax: 612-870-5491

Dr. Olalekan Hakeem Akanbi, MD Internal Medicine - Gastroenterology Medicare: Medicare Enrolled Practice Location: 10150 Niagara Ln N # 210, Maple Grove, MN 55369 Phone: 612-871-1145    Fax: 612-870-5491

Christopher Steevens, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 14500 99th Ave N, Maple Grove, MN 55369 Phone: 763-898-1000

News Archive

Adocia, Lilly terminate collaboration agreement relating to fast-acting insulin analog

Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announced today that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone(R) technology for the formulation of fast acting insulin analog formulated with the BioChaperone(R) technology. Consequently, the two companies have terminated the collaboration.

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Patrys Limited (ASX: PAB), which is developing a new class of antibody molecules for the treatment of cancer, is pleased to announce success in obtaining commercial production yields for natural human antibody PAT-SC1, facilitating the advancement of this promising product toward a second human clinical trial for the treatment of cancer.

Impact of Personal Genomics Study to launch data collection phase

As genetic risk information plays an increasingly important role in the diagnosis and treatment of many diseases, private companies have made personal genomic testing for these risk factors widely available to the public. However, very little data has been gathered to understand the motivations and expectations of consumers of personal genomic services, the psychological and behavioral impact of these services, and the associated ethical, legal and social issues—until now.

Researchers find better patient-reported quality of life in women who received pelvic IMRT

NRG Oncology investigators report better patient-reported quality of life measures for women who received intensity modulated radiation therapy (IMRT) for their pelvic radiation therapy (RT) than those who received standard RT.

FDA advisory panel recommends approval for Boston Scientific's CRT-D in treatment of mild heart failure

A new therapy that reduces the risk of mortality and heart failure in patients with mild cardiac disease received a thumb's up this week from an advisory panel to the U.S. Food and Drug Administration. The panel recommended that the cardiac resynchronization therapy defibrillator (CRT-D), tested extensively nationwide under the leadership of cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, be approved for use in patients with mild heart failure in the United States.

Read more Medical News

› Verified 7 days ago